Precision BioSciences Analyst Ratings
Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B
Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential
Precision BioSciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)
Maintaining Hold on Precision BioSciences Pending Clinical Data and Strategic Reassessments
Buy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong Financials
Precision BioSciences Analyst Ratings
Precision BioSciences Analyst Ratings
Buy Rating Affirmed for Precision BioSciences Amid Strong Gene Editing Prospects and Upcoming Milestones
BMO Capital Reaffirms Their Hold Rating on Precision BioSciences (DTIL)
Buy Rating Affirmed for Precision BioSciences on Promising Gene Editing Prospects and Strong Financials
Precision BioSciences Analyst Ratings
Buy Rating Affirmed for Precision BioSciences as Milestones in Gene Editing Technology Loom
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Actinium Pharmaceuticals (ATNM)
Precision BioSciences Analyst Ratings
Buy Rating Affirmed for Precision BioSciences Amid Progress in HBV Gene Therapy Program
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Precision BioSciences (DTIL) and Healthequity (HQY)
Promising Preclinical Results Support Buy Rating for Precision BioSciences' CHBV Treatment Program
Advancing Gene Editing Pipeline and Potential Breakthrough in HBV Treatment Boost Precision BioSciences' Buy Rating
No Data